- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05579184
[Lu-177]Ludotadipep in Castration-resistant Prostate Cancer(CRPC): Investigation of Drug and Application_2 (LUCIDA_2)
Phase 2 Study of Repeat-dose [177Lu]Ludotadipep Treatment for Metastatic Castration-resistant Prostate Cancer
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Seoul, Korea, Republic of
- The Catholic University of Korea, Seoul, St, Mary's Hospital, 222, Banpo-daero, Seocho-gu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Adult male over the age of 19 as of the date of written consent
- Adenocarcinoma confirmed by histopathology or cytology
- Those who have been confirmed with at least two metastases in the soft tissue lesions or bone lesions based on the PCWG3 modified RECIST v1.1 criterion for prostate adenocarcinoma, or those who experience pain due to radiologically apparent disease progression
Those with castration resistance with a blood testosterone level of 50 ng/dL or less at the time of screening and those who meet one or more of the criteria below
Prostate cancer patients with resistance against imaging-based progression of metastatic castration even after at least 4 weeks of imaging-based progression of standard medical treatment using one or more second-generation hormonal agents (e.g., enzalutamide, abiraterone) are administered in combination with standard taxene-based chemotherapy (e.g., docetaxel).
In cases where the patient is judged unsuitable by the investigator for the standard medical treatment specified above
- In cases where the patient himself/herself refuses the standard medical treatment specified above
- Those that exhibit lesions of 4 or higher PSMA reporting and data system (P-RADS) in the [18F] PSMA PET/CT imaging at the time of screening
- Those that exhibit higher or wider uptake of the lesion in [18F] PSMA PET/CT imaging than [18F] FDG PET taken at the time of screening as judged by the investigator
- Those who exhibit an ECOG performance score of level 2 or less at the time of screening and with an expected survival period of at least 6 months
Subjects having active sexual activities with a fertile female spouse must satisfy the following:
- If the spouse is a fertile woman (including pregnant and lactating women), the subject must consent to maintain abstinence or to use double contraception* from the time of screening and throughout the entire clinical trial period and at least 6 months after the administration of the last investigational drug.
Sperm of the subject must not be donated during the entire clinical trial period from the time of screening and for at least 6 months after the administration of the last investigational drug.
- Double contraception: If applicable to at least two of the following: the use of condoms, non-hormonal intrauterine device, diaphragm, cervical cap, if it has been more than 3 months since the male spouse had a vasectomy (at the time of initial screening visit), or the spouse is medically diagnosed with infertility
- Those who have fully understood the purpose, details, and characteristics of the investigational drug from the investigator before enrolling in the clinical trial and signed the informed consent form in person or by guardian or legal representative
Exclusion Criteria:
Those who are judged to have abnormalities in bone marrow, liver, or kidney function as they are in accordance with the results of laboratory tests that satisfy at least one of the following criteria at the time of screening:
If ANC is below 1.5 x 109/L
If Hemoglobin is below 9.0 g/dL
If the platelet count is below 100 x 109/L
If total bilirubin exceeds 1.5 times the normal value,
If serum albumin is below 2.5 g/dL
- If the glomerular filtration rate (eGFR) is below 50 mL/min
Those with one or more of the following diseases at the time of screening
Those who correspond to Classification III-IV under the New York Heart Association (NYHA) classification of patients with severe heart failure
Patients with uncontrolled hypertension (SBP > 160 mm Hg or DBP > 90 mm Hg)
- Patients with uncontrolled diabetes (HbA1c > 7.0% or fasting blood sugar > 160 mg/dL)
- Those with a history of prostate cancer or solid cancer other than radical metastasis limited to bone or soft tissue with basis on prostate cancer or blood cancer including lymphoma within 3 years from the time of screening (However, non-melanoma skin cancer, superficial bladder cancer, thyroid cancer, and intraepithelial carcinoma (carcinoma in situ) that do not require continued treatment as they are treated appropriately and remain disease-free within 2 years from the time of screening)
- Those who have received radiopharmaceutical treatment or radiotherapy for the target lesion of metastatic prostatic carcinoma within 12 weeks from the time of screening
- Those with active infection of HIV, HBV, HCV, or VDRL at the time of screening, or those with other uncontrolled active infectious diseases with proteinuria of > 1.0 in protein under the urine protein vs. creatinine ratio
- Those suffering from one or more disease of the following: Immunosuppressive status (including nephrectomy, hematopoietic stem cell transplantation) and autoimmune disease patients (including severe myasthenia, Hashimoto thyroiditis, rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus, scleroderma) at the time of screening
- Those who had participated in a therapeutic clinical trial within 30 days of screening and had been administered or applied with other investigational products or investigational devices.
- Those with potential hypersensitivity reaction to this investigational product [177Lu] ludotadipep
- Those with an anamnesis of clinically significant mental illness, alcohol abuse, etc.
- Those who are judged unsuitable by the investigator to participate in this clinical trial for other miscellaneous reasons or who are judged incompatible with the administration requirements
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: [177Lu]Ludotadipep 100 mCi
100 mCi of [177Lu] ludotadipep shall be administered to the subject repeatedly up to 6 times at intervals of 8 weeks (±2 weeks).
|
Patients will receive 100 mCi of [177Lu]Ludotadipep every 8 [±1] weeks (up to 6 times)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Prostate-Specific Antigen Response Rate (PSA-RR)
Time Frame: up to 48 weeks (Response Rate from Baseline to EOT(End of Treatment))
|
Defined as the proportion of participants with a PSA reduction of ≥ 50% from baseline
|
up to 48 weeks (Response Rate from Baseline to EOT(End of Treatment))
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Prostate-Specific Antigen Response Rate (PSA-RR)
Time Frame: Between 4 and 6 weeks after treatment
|
The prostate-specific antigen response rate (PSA-RR) is assessed after the administration of [177Lu]Ludotadipep
|
Between 4 and 6 weeks after treatment
|
Changes in the Standardized Uptake Values (SUV) of [18F]PSMA PET/CT
Time Frame: up to 48 weeks (up to 6 doses at 8-weekly intervals [± 1 week], with 6 week follow-up after each dose (Screening up to 28 days)
|
The tumor response is assessed by comparing the changes in the Standardized Uptake Values (SUV) of [18F]PSMA PET/CT after administration of [177Lu]Ludotadipep compared to pre-administration
|
up to 48 weeks (up to 6 doses at 8-weekly intervals [± 1 week], with 6 week follow-up after each dose (Screening up to 28 days)
|
Objective Response Rate (ORR)
Time Frame: up to 48 weeks (up to 6 doses at 8-weekly intervals [± 1 week], with 6 week follow-up after each dose (Screening up to 28 days)
|
The objective response rate (ORR) is assessed after administration of [177Lu]Ludotadipep
|
up to 48 weeks (up to 6 doses at 8-weekly intervals [± 1 week], with 6 week follow-up after each dose (Screening up to 28 days)
|
The Best Objective Response Rate (BORR)
Time Frame: up to 48 weeks (up to 6 doses at 8-weekly intervals [± 1 week], with 6 week follow-up after each dose (Screening up to 28 days)
|
The best objective response rate (BORR) is assessed after administration of [177Lu]Ludotadipep
|
up to 48 weeks (up to 6 doses at 8-weekly intervals [± 1 week], with 6 week follow-up after each dose (Screening up to 28 days)
|
Progression-Free Survival (PFS)
Time Frame: up to 48 weeks (up to 6 doses at 8-weekly intervals [± 1 week], with 6 week follow-up after each dose (Screening up to 28 days)
|
The imaging-based progression-free survival (PFS) is assessed after administration of [177Lu]Ludotadipep
|
up to 48 weeks (up to 6 doses at 8-weekly intervals [± 1 week], with 6 week follow-up after each dose (Screening up to 28 days)
|
Objective Response Rate (ORR)
Time Frame: up to 48 weeks (up to 6 doses at 8-weekly intervals [± 1 week], with 6 week follow-up after each dose (Screening up to 28 days)
|
The objective response rate (ORR) is assessed while using PCWG3 modified RECIST V1.1 after administration of [177Lu]Ludotadipep
|
up to 48 weeks (up to 6 doses at 8-weekly intervals [± 1 week], with 6 week follow-up after each dose (Screening up to 28 days)
|
Pain response rate
Time Frame: up to 48 weeks (up to 6 doses at 8-weekly intervals [± 1 week], with 6 week follow-up after each dose (Screening up to 28 days)
|
≥2 point reduction in Present Pain Intensity Scale (PPI) score from baseline with no increase in analgesic score; and/or ≥50% decrease in analgesic score with no increase in PPI using the McGill Questionnaire
|
up to 48 weeks (up to 6 doses at 8-weekly intervals [± 1 week], with 6 week follow-up after each dose (Screening up to 28 days)
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Ji Youl Lee, Ph.D, The Catholic University of Korea
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- FC705-2
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metastatic Castration-resistant Prostate Cancer, mCRPC
-
BayerCompletedMetastatic Castration-resistant Prostate Cancer (mCRPC)United States
-
BayerCompletedMetastatic Castration Resistant Prostate Cancer (mCRPC)United States
-
Jiangsu HengRui Medicine Co., Ltd.CompletedMetastatic Castration-resistant Prostate Cancer (mCRPC)China
-
Memorial Sloan Kettering Cancer CenterProgenics Pharmaceuticals, Inc.CompletedProstate Cancer | Metastatic Castration-Resistant Prostate Cancer (mCRPC)United States
-
Jiangsu HengRui Medicine Co., Ltd.RecruitingMetastatic Castration-Resistant Prostate Cancer (mCRPC)Korea, Republic of, United States, Spain, France, Belgium, China, Taiwan, United Kingdom, Australia, Czechia, Hungary, Poland, Russian Federation
-
Constellation PharmaceuticalsActive, not recruitingMetastatic Castration Resistant Prostate Cancer (mCRPC)United States
-
Avionco LLCCompletedMetastatic Castration-Resistant Prostate Cancer (mCRPC)Russian Federation
-
UNC Lineberger Comprehensive Cancer CenterWithdrawnMetastatic Castration Resistant Prostate Cancer (mCRPC)United States
-
PfizerCompletedMetastatic Castration Resistant Prostate Cancer (mCRPC) | Metastatic Castration Sensitive Prostate Cancer (mCSPC)Finland
-
Myovant Sciences GmbHRecruitingMetastatic Castration-Resistant Prostate Cancer | Metastatic Castration-Sensitive Prostate Cancer | Non-Metastatic Castration-Resistant Prostate CancerUnited States
Clinical Trials on [177Lu]Ludotadipep
-
FutureChemCompletedMetastatic Castration-resistant Prostate CancerKorea, Republic of
-
FutureChemRecruitingMetastatic Castration-resistant Prostate CancerUnited States
-
IpsenTerminatedGastric Cancer | Colorectal Cancer | Bone Cancer | Squamous Cell Carcinoma of the Head and Neck | Advanced Cancer | Recurrent Disease | Pancreatic Ductal Adenocarcinoma | Metastatic TumoursUnited States, France, Belgium, Switzerland, Netherlands
-
Sidney Kimmel Comprehensive Cancer Center at Johns...Adenoid Cystic Carcinoma Research Foundation; Progenics Pharmaceuticals, Inc.Not yet recruitingAdenoid Cystic CarcinomaUnited States
-
The First Affiliated Hospital of Xiamen UniversityRecruiting
-
Telix International Pty LtdNot yet recruiting
-
Yantai LNC Biotechnology Singapore PTE. LTD.Not yet recruitingMetastatic Castration-resistant Prostate Cancer, mCRPC
-
Yantai LNC Biotechnology Singapore PTE. LTD.Recruiting
-
Peking Union Medical College HospitalRecruitingMetastatic Castration-resistant Prostate CancerChina
-
Peter MacCallum Cancer Centre, AustraliaRecruitingProstate Cancer | Metastatic Castration-resistant Prostate CancerAustralia